NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Abstract Parkinson’s disease (PD) is a progressive neurodegenerative disorder mainly distinguished by sporadic aetiology, although a genetic component is also well established. Variants in the LRRK2 gene are associated with both familiar and sporadic forms of the disease. We have previously shown that PAK6 and 14-3-3γ interact with and regulate the activity of LRRK2. In this study, we quantify the total amount of PAK6 and 14-3-3γ both in post-mortem tissue and in plasma samples to explore their potential as novel biomarkers for PD. The amount of PAK6 and 14-3-3γ is significantly different in PD patients compared to healthy subjects; moreover, PAK6 also varies with the presence of the G2019S mutation in the LRRK2 gene. These observations were further confirmed by generalized linear models. We suggest that changes of PAK6 and 14-3-3γ in plasma represent a shared readout for patients affected by sporadic and LRRK2-related PD and they may be added in a broader panel of biomarkers for PD.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.